Elucidation of the Phase I and Phase II metabolic pathways of (±)-4′-methylmethcathinone (4-MMC) and (±)-4′-(trifluoro- methyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MS2. J Pharm Biomed Anal. 2013;72:177-185....
In this research, on-line electrochemistry coupled quadrupole time-of-flight mass spectrometry (EC/Q-TOF/MS) was used to simulate the oxidative metabolism of Citrus flavonoids (such as naringenin, naringin, hesperetin, hesperidin and nobiletin). The phase I and phase II (GSH adduct) metabolic ex...
The dramatic explosion of the personal computer industry has had a tremendous effect on the business computing and information services needs for large corporations. The demand for more information, faster, to a wider range of employees within a corporation has rapidly moved the corporate computing en...
QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-life (t1/2) for CTLA-4. We report results from a phase I/Ib study of QL1706...
a CYH33 and b its active metabolite I27 Concentration-Time Profiles (Mean ± SD) on Cycle 1 Day 1 (1 mg, n = 1; 5 mg, n = 1; 10 mg, n = 2; 20 mg, n = 5; 30 mg, n = 12; 40 mg, n = 3; 60 mg, n = 4); ...
A phase I/II study utilising a new schedule for this combination was conducted. METHODS: A biweekly regimen of docetaxel on day 1 with oral S-1 on days 1–7 was administered to previously treated NSCLC patients. Doses of docetaxel/S-1 were escalated to 30/80, 35/80, and 40/80 mg ...
BM William,MS Allen,FR Loberiza,RG Bociek,JM Vose 摘要: A phase I/II trial was designed to evaluate the safety and activity of adding bortezomib to standard BEAM (BCNU, etoposide, cytarabine, melphalan) and ASCT. Eligible patients (pts) had relapsed/refractory indolent or transformed NHL or...
An MTD of 35 mg/mLE-SN38 was found for patients. Since and patients did not appear to exhibit clinically significant differences in safety or PK profiles, this dose will be evaluated in both groups in a Phase II study of patients with colon cancer. 展开 ...
FULL PAPER British Journal of Cancer (2018) 118, 770–776 | doi: 10.1038/bjc.2017.484 Keywords: AZD0424; Src; ABL; Phase I; targeted therapy A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ ABL inhibitor AZD0424 Victoria K Woodcock1, Sally Clive2...
The aim of this randomised phase II trial was to evaluate the feasibility and activity of weekly docetaxel/gemcitabine (DG) followed by erlotinib after progression (arm A) vs erlotinib followed by DG after progression (arm B) in fit elderly patients with advanced non small-cell lung cancer (...